Cigna's Specialty Pharmacy Leadership Expected to Drive Long-Term EPS Growth, Analyst Says
Portfolio Pulse from Vandana Singh
Piper Sandler has initiated coverage on Cigna Corporation (NYSE:CI) with an Overweight rating and a price target of $400. The analyst highlights Cigna's leadership in the specialty pharmacy market and its strong EPS growth potential. Cigna's businesses, Cigna Healthcare and Evernorth Health Services, are expected to drive long-term EPS growth at a 10-14% CAGR. The sale of the Medicare Advantage business to HCSC is seen as a positive catalyst for 2025.
June 26, 2024 | 6:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Cigna Corporation with an Overweight rating and a price target of $400. The analyst highlights Cigna's leadership in the specialty pharmacy market and its strong EPS growth potential. The sale of the Medicare Advantage business to HCSC is seen as a positive catalyst for 2025.
The Overweight rating and $400 price target from Piper Sandler are positive signals for Cigna's stock. The company's leadership in the specialty pharmacy market and strong EPS growth potential are key factors. The sale of the Medicare Advantage business to HCSC is also seen as a positive catalyst for 2025.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100